Navigation Links
Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
Date:11/1/2011

DEERFIELD, Ill., Nov. 1, 2011 /PRNewswire/ -- Takeda Global Research & Development Center, Inc., (Takeda) announced that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 25, 2012 for the review of its investigational type 2 diabetes therapy alogliptin, and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.  

Currently, the FDA is reviewing the new drug applications (NDA) for the investigational therapies, which were resubmitted on July 25, 2011; the FDA has categorized these as Class 2 responses, requiring up to six months for review. Alogliptin is a selective dipeptidyl peptidase IV inhibitor (DPP-4i) under investigation in the United States (U.S.) for the treatment of type 2 diabetes as an adjunct to diet and exercise. Discovered by Takeda San Diego, Inc., alogliptin is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide), which play a role in regulating blood glucose levels. Pioglitazone was approved in 1999 for the treatment of type 2 diabetes as an adjunct to diet and exercise. If approved, alogliptin/pioglitazone will be the first type 2 diabetes treatment option in the U.S. to include both a DPP-4 inhibitor and a thiazolidinedione (TZD) in a single tablet.

According to the International Diabetes Federation, a staggering 285 million individuals were living with diabetes worldwide in 2010.

"As recent figures indicate that diabetes continues to be a serious global health challenge, Takeda remains deeply committed to researching new and important therapeutic options for patients living with type 2 diabetes," said David Recker, M.D., senior vice president, clinical science, Takeda Global Research & Development Center. "Phase 3 studies have demonstrated that the combination of a
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
2. Takeda Completes Acquisition and Names New CEO of Nycomed
3. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
4. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
5. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
6. Takeda to Acquire Nycomed
7. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
8. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
9. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
10. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
11. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... -- Releases of the genetically engineered Oxitec ... , , reduced the dengue mosquito population in an ... 95%, well below the modelled threshold for epidemic disease ... The journal PLOS Neglected Tropical Diseases published today the ... The results showed that in Juazeiro city, northeast ...
(Date:7/2/2015)... 2, 2015 According to a new ... Brain Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, ... to 2020", published by MarketsandMarkets, the global Neuromodulation Market is ... reach $6.20 Billion by 2020, at a CAGR of 11.2% ... 8 4 market data T ables ...
(Date:7/2/2015)... , June 25, 2015 Research ... "Cancer Diagnostics Market by Technology, Imaging and by Application - Forecast ... cancer diagnostics market is expected to reach $13.1 Billion in 2020 ... of 12.9%. The market is dominated by ... Asia , and Rest of the World (RoW). ...
Breaking Medicine Technology:Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2
... InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the ... today announced that it has filed its Form 10-Q for ... Securities and Exchange Commission. The Company provided an update on ... During March and April 2011, InspireMD completed ...
... Pa., May 17, 2011 TechPrecision Corporation (OTC ... "the Company"), an industry leading manufacturer of precision, ... with customers in the alternative energy, cleantech, medical, ... announced that it has received orders from three ...
Cached Medicine Technology:InspireMD Announces Year-to-Date 2011 Progress 2InspireMD Announces Year-to-Date 2011 Progress 3InspireMD Announces Year-to-Date 2011 Progress 4InspireMD Announces Year-to-Date 2011 Progress 5TechPrecision Corporation Receives $1.6 Million in New Orders from Existing Customers 2TechPrecision Corporation Receives $1.6 Million in New Orders from Existing Customers 3
(Date:7/3/2015)... ... July 03, 2015 , ... The Celebrity Dresses is currently running ... to those of celebrities will have the opportunity to get 10% discount on orders ... that people do not have to use coupon codes or remember redemption codes. ...
(Date:7/2/2015)... , ... July 02, 2015 , ... Following the recent ... the number of obese Americans outnumber merely overweight Americans, Samir Becic emphatically declared a ... threats to American society right now," Becic said. "We must understand the magnitude of ...
(Date:7/2/2015)... ... ... swing, Americans are flocking to Canada’s many lakes to reel in their fair share of ... it’s easy to understand why. From the Pacific Northwest Coast of British Columbia to the ... huge industry, and Americans make up the vast majority of anglers from outside of Canada. ...
(Date:7/2/2015)... ... July 02, 2015 , ... Get ready ... SIGVARIS PERFORMANCE SOCKS. Since the socks were first introduced, they have rapidly been ... popularity has inspired four new, fun shades including: blue, lime, pink and red. ...
(Date:7/2/2015)... San Diego, CA (PRWEB) , ... July 02, 2015 , ... ... lifestyle and a passion for social fitness. Built to function as a lifestyle community, ... while giving them the opportunity to network, meet, and participate in discussions or group ...
Breaking Medicine News(10 mins):Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2
... ... Internationally recognized child and family therapy pioneer B. ... on healthy newborn attachment and emotional development for Miracle Industries, LLC., ... partnership, branded Post Miracle Parenting™, will offer a valuable online resource ...
... ... enhances its North American indoor product offering with a more complete and innovative range ... launch of www.tarkettsportsindoor.com . , ... (PRWEB) November 9, 2009 -- Tarkett Sports, redesigned line of North ...
... Awareness Month Highlighted During Broadcast , WASHINGTON, Nov. 9 ... and friends will ring The Closing Bell for the New ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO ) , ... advocate, Richard Heimler will mark the end of the day,s ...
... 9 Sutter Health, a family of doctors, not-for-profit ... $255,000 to food banks across Northern California. A variety ... to help put much-needed meals on the tables of ... , Sutter Health has a long history of partnering ...
... House action backs President Obama,s promise to not expand ... , Bishops still concerned for poor, elderly , ... of the United States Conference of Catholic Bishops, lauded the ... block federal health care reform money from paying for elective ...
... , MONDAY, Nov. 9 (HealthDay News) -- Obesity is a ... risk of atrial fibrillation, stroke and death, a new study ... arrhythmia (an irregular heart rhythm or heartbeat). , Researchers ... 74, in Germany who were followed for 10 years. The ...
Cached Medicine News:Health News:Attachment & Emotional Development Expert Teams Up with Miracle Industries, LLC. to Launch Valuable Parenting Resource 2Health News:Attachment & Emotional Development Expert Teams Up with Miracle Industries, LLC. to Launch Valuable Parenting Resource 3Health News:Attachment & Emotional Development Expert Teams Up with Miracle Industries, LLC. to Launch Valuable Parenting Resource 4Health News:Tarkett Sports Launches Revamped Indoor Sports Flooring Division and New Indoor Website 2Health News:Lung Cancer Alliance Staff and Advocates to Ring Closing Bell of New York Stock Exchange(TM) 2Health News:Sutter Health Donates $255,000 to Help the Hungry This Holiday Season 2Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 2Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: